These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25792728)

  • 1. Mogamulizumab: 2 birds, 1 stone.
    Wilcox RA
    Blood; 2015 Mar; 125(12):1847-8. PubMed ID: 25792728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
    Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
    Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 5. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
    Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
    Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR4 and its ligands: from bench to bedside.
    Yoshie O; Matsushima K
    Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
    Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
    Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
    Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
    Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.
    Oymanns M; Daum-Marzian M; Assaf C
    Curr Oncol; 2024 Sep; 31(9):5412-5421. PubMed ID: 39330028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
    Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
    Mukai M; Mould D; Maeda H; Narushima K; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.